ERBB2 and breast carcinoma: Unfortunately, either intrinsic or acquired resistance occurred in approximately 15-20% of ER+ HER2 negative breast cancer patients (50), with adverse effects in some patients, such as neutropenia in response to ribociclib and palbociclib (51).